Search research articles
Contact Us
Filters
Showing results (121-130 of 196) with videos related to
Page
of 20
Sort By:
Plos One
|
August 21, 2018
Cognition among individuals along a spectrum of increased risk for Parkinson's disease
Lana M Chahine, Liz Urbe, Chelsea Caspell-Garcia, et al.
Nature Medicine
|
October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial
Gennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Annals of Clinical and Translational Neurology
|
October 31, 2014
Overcoming obstacles to repurposing for neurodegenerative disease
Diana W Shineman, John Alam, Margaret Anderson, et al.
JAMA Neurology
|
January 6, 2025
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial
Niraj M Shanbhag, Jaya L Padmanabhan, Zheng Zhang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 Years
Tanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Annals of Clinical and Translational Neurology
|
March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease
Paulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
NPJ Parkinson'S Disease
|
February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
Kalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
Parkinsonism & Related Disorders
|
January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
JAMA Neurology
|
December 14, 2020
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
Tanya Simuni, Brian Fiske, Kalpana Merchant, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 196) with videos related to
Sort By:
Page
of 20
Plos One
|
August 21, 2018
Cognition among individuals along a spectrum of increased risk for Parkinson's disease
Lana M Chahine, Liz Urbe, Chelsea Caspell-Garcia, et al.
Nature Medicine
|
October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial
Gennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Annals of Clinical and Translational Neurology
|
October 31, 2014
Overcoming obstacles to repurposing for neurodegenerative disease
Diana W Shineman, John Alam, Margaret Anderson, et al.
JAMA Neurology
|
January 6, 2025
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial
Niraj M Shanbhag, Jaya L Padmanabhan, Zheng Zhang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 Years
Tanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Annals of Clinical and Translational Neurology
|
March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease
Paulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
NPJ Parkinson'S Disease
|
February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
Kalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
Parkinsonism & Related Disorders
|
January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
JAMA Neurology
|
December 14, 2020
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
Tanya Simuni, Brian Fiske, Kalpana Merchant, et al.
Page
of 20